Cyclic peptide drug discovery company 20n Bio secures $7.5 million Seed+ financing to advance its AI-powered cyclic peptide discovery platform and innovative drug pipeline

20n Bio, a biotechnology company focused on cyclic peptide drug discovery, today announced the completion of a $7.5 million Seed+ financing round. The round was led by a leading industrial strategic investor, with participation from a London-based life science venture capital fund. The proceeds will be primarily used to further strengthen 20n Bio's high-throughput cyclic peptide discovery platform, integrate AI technologies across the cyclic peptide discovery and optimization process, and advance the Company's proprietary innovative drug pipeline.

20n Bio is developing a next-generation technology platform for cyclic peptide drug discovery and optimization. Cyclic peptides are a class of drug molecules highly amenable to platform-based discovery and engineering development, holding broad potential in targeted delivery, radiotherapeutics, oral peptide drugs, and addressing historically undruggable targets. 20n Bio's platform enables rapid discovery of high-affinity, high-selectivity cyclic peptide binders against a wide range of disease-related targets from ultra-large cyclic peptide libraries. The Company has demonstrated de novo cyclic peptide discovery capabilities across multiple targets; several molecules discovered through the platform have generated in vivo data through out-licensed programs, further supporting the translational potential of the platform's discovered molecules.

Over the past several years, 20n Bio has made significant progress in platform development and strategic collaborations. The Company was selected for Bayer Co.Lab and has established a strategic partnership with Lannacheng Biotech, a leading radiopharmaceutical company in China, to jointly explore the application of cyclic peptide technology in precision oncology and radiotherapeutic development.

Upon completion of this financing round, 20n Bio will continue to pursue its dual-engine strategy of parallel platform collaborations and proprietary pipeline development. On one hand, through its high-throughput cyclic peptide discovery platform, 20n Bio will provide high-quality targeting molecules for innovative drug programs of its industry partners. On the other hand, 20n Bio will advance its internal pipeline development around areas with clear clinical rationale and well-defined translational paths, accelerating the discovery and translation of next-generation cyclic peptide therapeutics.